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Abstract
Background—The plasma kallikrein-kinin
(K-K) system is activated in acute and
chronic relapsing intestinal inflammation
induced in Lewis rats by intramural injec-
tion of exogenous bacterial components.
Aims—To determine whether this eVect is
model specific, K-K system activation was
investigated in a modified indomethacin
induced enterocolitis model, as well as
bradykinin 2 (B2) receptor distribution in
the normal and acutely inflamed intestine.
Methods—Lewis rats injected with daily
sublethal doses of indomethacin for two
days developed acute (two days) and
chronic (14 days) intestinal inflammation.
Plasma prekallikrein (amidolytic), high
molecular weight kininogen (HK, coagu-
lant) and cleavage of HK (western blot)
were assayed to detect K-K activation.
Results—Liver and spleen weights were
significantly higher, and body weights and
haematocrit values were significantly
lower in the indomethacin group than in
the control group. During both acute and
chronic phases, rats displayed K-K system
activation manifested by a significant
decrease in plasma prekallikrein and HK
functional levels, and by HK cleavage.
Plasma T kininogen (a major acute phase
protein) was significantly elevated. B2
receptors were identified in both normal
and inflammatory intestine with more
prominent specific immunohistochemical
staining in the acutely inflamed tissue.
Conclusions—K-K system activation oc-
curs in association with both acute and
chronic phases of intestinal injury, re-
gardless of the triggering agent, suggest-
ing that activation of this system is
integrally involved in intestinal inflamma-
tion in genetically susceptible hosts. Lo-
calisation of B2 receptors across intestinal
layers provides a structural basis for the
kinin function in the intestine.
(Gut 1998;43:365–374)
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Idiopathic inflammatory bowel diseases (IBD),
including Crohn’s disease and ulcerative coli-
tis, are complex disorders with multiple patho-
genic factors including cellular and humoral
inflammatory cascades, genetic susceptibility,
and environmental influences.1 The aetio-
pathogenesis of IBD is incompletely under-
stood; however, progress is being made owing
to the development of improved animal models
of enterocolitis.2 Enteric bacteria have long
been postulated to play an important role by
initiating or perpetuating intestinal inflamma-
tion in the genetically susceptible host.1
Peptidoglycan-polysaccharide (PG-PS), a bac-
terial cell wall polymer common to most bacte-
ria, is used as an inducer of intestinal and
extraintestinal inflammation in one of the rat
enterocolitis models that we employ.3 The
inflammatory response initiated by PG-PS is
similar to that present in human IBD in that it
is mediated by leucocyte activation with libera-
tion of cytokines and eicosanoids, and activa-
tion of plasma proteolytic pathways.1 4 Re-
cently, we have shown that activation of the
kallikrein-kinin (contact) system occurs in
acute5 and chronic relapsing3 intestinal inflam-
mation induced in Lewis rats by intramural
intestinal injection of PG-PS derived from
group A streptococci. This model requires a
specific genetic background as only susceptible
Lewis rats (but not resistant BuValo rats)
develop chronic, relapsing, granulomatous
intestinal and systemic inflammation with
associated activation of the kallikrein-kinin
system.3
The plasma contact system comprises factor
XII, prekallikrein (PK), and factor XI (FXI),
which are zymogens of proteases, and high
molecular weight kininogen (HK), which
serves as the cofactor of contact activation.6
The consequences of activation of this system
include the conversion of PK to the proteolytic
enzyme, kallikrein, which releases bradykinin
fromHK, and activation of FXI to FXIa, which
may contribute to the intrinsic coagulation
pathway.6 Kallikrein is a chemoattractant for
neutrophils, which it stimulates to aggregate7
and release elastase8 and superoxides.9 Plasma
kallikrein cleaves HK in a three step pattern. In
humans, the first cleavage yields a heavy chain
of HK (64 kDa) and a light chain of HK (56
kDa) on a reduced sodium dodecyl sulphate
(SDS) gel. The second cleavage yields bradyki-
nin. The third cleavage results in a stable kinin
free protein (64 kDa and 45 kDa chains), and
additional small peptides. Bradykinin is a
potent inflammatory mediator which expresses
a biological eVect by activating constitutive B2
receptors, whereas des-Arg9 bradykinin, its
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induced by inflammatory cytokines, on en-
dothelial cells, smooth muscle cells, epithelial
cells, and fibroblasts.10 In the intestine, brady-
kinin acting through B2 receptors has been
implicated in ion transport, pain induction,
and motility.11 However, B2 receptor distribu-
tion in the intestinal layers has not been
described.
Activation of the kallikrein-kinin system is
directly involved in the pathogenesis of PG-PS
induced intestinal injury. We have documented
that a specific plasma kallikrein inhibitor
attenuates acute5 and chronic12 phases of intes-
tinal inflammation. Activation of the kallikrein-
kinin system has been implicated in various
other experimental inflammatory13 14 and
human disease15 states in which exogenous
bacterial products such as endotoxin (lipopoly-
saccharide, LPS) seem to be aetiologically
important. The similarity of biological re-
sponses to LPS and PG-PS coincides with the
ability of both bacterial products to induce
similar cytokines and mediators.4 However, it is
not clear whether activation of the kallikrein-
kinin pathway is limited to enterocolitis models
triggered by exogenous bacterial polymers or
whether it could be generalised to other
experimental intestinal inflammatory condi-
tions and, ultimately, to human IBD. There-
fore, we investigated whether the kallikrein-
kinin system is activated in an enterocolitis
model induced by a chemical substance,
indomethacin.
A recent modification of the indomethacin
induced enterocolitis model16 to induce
chronic mid small intestinal inflammation in
genetically susceptible Lewis rats has been
described in a preliminary communication. In
the current study, we used this reproducible
model to quantify the inflammatory response
measuring macroscopic, histological, and bio-
chemical markers of intestinal inflammation
and evaluated extraintestinal complications.
We measured T kininogen, the major type 2
acute phase protein in the rat, which increases
strikingly in inflammatory reactions.17 To assess
the participation of the kallikrein-kinin system,
we measured the plasma contact proteins and
analysed the HK cleavage pattern qualitatively.
In order to visualise the B2 receptors which
mediate the proinflammatory eVect of the
kinins, we employed immunohistochemistry
with antibodies to specific amino acid se-
quences (peptides) in the receptor. The results
indicate that activation of the kallikrein-kinin
system is not limited to intestinal inflammation
induced by exogenous bacterial products. The
present study also indicates that kinin may
mediate intestinal inflammation through B2
receptors which we visualised for the first time
in the intestinal layers.
Methods
MATERIALS
The chromogenic substrates S-2302
(prekallikrein/kallikrein), S-2366 (factor XI),
and plasma prekallikrein activator were pur-
chased from Pharmacia (Franklin, Ohio).
Microplates (no. 3075) were obtained from
Falcon Plastic (Mt Laurel, New Jersey).
Indomethacin was purchased from Sigma (St
Louis, Missouri).
EXPERIMENTAL PROTOCOL
A total of 36 female inbred Lewis rats (Charles
River Laboratories, Raleigh, New Carolina),
mean weight 180 g, was used. Rats were
housed in pathogen free conditions and fed
standard rat chow and water. The experiment
was performed to evaluate both the acute phase
(two day) and chronic phase (14 day) of
inflammation. Rats were separated into two
groups. The treated animals received two sub-
cutaneous injections of indomethacin (7.5
mg/kg in 0.3 ml buVer daily at 24 hour
intervals). To prepare this buVer, indomethacin
was first dissolved in absolute ethanol (50
mg/ml) and then diluted fivefold with 0.1 M
NaHCO3, pH 7.0, filtered, and diluted in 0.1
M NaHCO3 to final concentration. The
control animals were injected subcutaneously
twice with 20% ethanol in 0.1 M NaHCO3.
Animals were killed by inhalation of 100%CO2
(eight controls and 13 experimental in the
acute phase; and seven controls and eight
experimental in the chronic phase). Cardiac
blood was aspirated from the right ventricle by
an 18 gauge needle into a syringe containing
3.8% sodium citrate (9/1, vol/vol) for coagula-
tion assays and 20 mM EDTA for haemato-
logical measurements. In addition, in some rats
blood was anticoagulated with a mixture of
protease inhibitors containing polybrene (400
µg/ml), EDTA (20 mM), benzamidine (100
mM), and soybean trypsin inhibitor (2 mg/ml)
for western blot analysis. Citrated blood was
twice centrifuged at 23°C to obtain the plasma
and then stored at −70°C.
ASSESSMENT OF INTESTINAL INFLAMMATION
At necropsy, intestinal inflammation was quan-
titated by gross examination by an observer
blinded to the identity of the rat as experimen-
tal or control, and tissue was collected for his-
tological evaluation and biochemical analysis.
A gross gut score was calculated using the sum
of 0–4 determinations of intestinal wall thick-
ening, adhesions, and mesenteric contraction.
This score is a minor modification of the
method previously validated in the PG-PS
enterocolitis model,3 removing only the deter-
mination for serosal nodules, which do not
occur following indomethacin injection. The
maximum gross score was 12. The most
involved 10 cm segment of small bowel was
then excised and opened longitudinally, and
mucosal ulcers were counted in the small
bowel. We also measured the percentage of the
mucosal surface area which was ulcerated in
this 10 cm segment. The tissue was divided in
half and prepared for histology and tissue
interleukin 1â (IL-1â) determinations. Tissue
was homogenised in 20 mM phosphate buVer
(pH 7.4) and centrifuged at 6000 g for 20 min-
utes at 4°C. The supernatant was assayed for
IL-1â using a previously described enzyme
linked immunosorbent assay (ELISA) pro-
vided and developed by Dr S Poole, National
Institute of Biostandards and Controls Labora-
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tory, Herefordshire, UK.18 Results were ex-
pressed as units of IL-1â activity per gram wet
tissue weight. A blinded histological score was
calculated as follows on tissues fixed in 10%
buVered formalin and stained with haematoxy-
lin and eosin. For each of four segments of
small intestine scored, an acute histology score
of 0–4+ was given as follows: 0, no injury; 1+,
infiltration of scattered neutrophils; 2+, infil-
tration of numerous neutrophils, no ulceration;
3+, superficial ulceration with preservation of
the submucosa and muscle layers; 4+, trans-
mural necrosis with abscess. Chronic histologi-
cal inflammation was scored as: 1+, focal scat-
tered mononuclear cell infiltration; 2+,
infiltration of numerous mononuclear cells; 3+,
thickening of submucosa with confluent mono-
nuclear cells adjacent to ulcer; 4+, distortion of
architecture with dramatic thickening of cell
layers. The acute and chronic score of each
segment was added, and a mean histological
score (maximum score 8, minimum score 0)
calculated from all segments studied.The gross
gut score and the mean histological score are
tabulated separately for the acute phase of
enterocolitis (day 2) and the chronic phase of
enterocolitis (day 14).
DETERMINATION OF SYSTEMIC COMPLICATIONS
Rats were weighed just before each indometh-
acin injection and at days 2 and 14. At
necropsy, liver and spleen were excised and
weighed and results were expressed as organ
Figure 1 Histological evidence of enteritis induced by indomethacin in female Lewis rats. (A) At day 2, after
subcutaneous injection of 7.5 mg/kg indomethacin for two days, a large ulcer with relatively bland necrosis of the entire
mucosa is seen with severe serosal and mesenteric inflammation with neutrophils and macrophages (original magnification
×100). (B) At day 14, there is an extensive ulcer with an active mucosal exudate. A crypt abscess is visible (arrow) and
glandular dysplasia with depletion of goblet cells. Transmural inflammation with thickening of the submucosa is evident.
The infiltrate consists of both mononuclear cells and neutrophils with fibroblast proliferation and smooth muscle hypertrophy.
Collagen indicative of early fibrosis is present (original magnification ×100).
Figure 2 Gross appearance of intestinal inflammation in indomethacin treated Lewis rats. (A) Thickening of the bowel wall with creeping mesenteric fat
(closed arrow) and adhesions (open arrow) is present at day 14 after injection of indomethacin on days 0 and 1. (B) Longitudinal ulcers (arrow) on the
mesenteric border are seen in the mid small bowel at day 14.
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weight in mg/g body weight. Haematocrit of
cardiac blood was determined.
ASSAYS OF CONTACT ACTIVATION
PK levels were determined by a functional
amidolytic assay as described in our
laboratory.19 Factor XI functional levels were
measured as previously described.20 HK coagu-
lant activity was evaluated by our
modification5 21 (using total kininogen deficient
plasma) of the method originally described by
Proctor and Rapaport.22 In addition, total pro-
tein values in rat plasma were measured using
the BCA protein assay (Pierce Laboratories)
according to the method described by
Bradford.23
WESTERN BLOT ANALYSIS OF CLEAVAGE OF RAT
PLASMA HK
IgG was purified from rabbit antiserum against
rat HK obtained from Dr A Adam using a pro-
tein A column.24 The purified IgG was labelled
with biotin according to the method described
by Hock et al.25 The specificity and sensitivity
of these antibodies to HK were analysed by
western blotting (see later), and the antibodies
were found to cross react weakly with rat serum
albumin and T kininogen, both of which
migrate as 68 kDa proteins. To evaluate HK
activation in vitro, pooled Lewis rat plasma was
activated with kaolin (Fisher Scientific) 1
mg/ml in buVered saline, in proportion (9/1,
vol/vol) at 23°C.3 After 20 minutes incubation,
the aliquots containing 30 µg protein of either
Lewis rat plasma or the same plasma activated
with kaolin were removed for western blot
analysis. Similarly, the plasma samples contain-
ing 30 µg protein of three representative
control rats and three indomethacin treated
rats were assayed on western blots to detect
HK cleavage. Western blotting was performed
as previously described.3
DETERMINATION OF T KININOGEN IN RAT PLASMA
T kininogen was measured by sandwich
ELISA as previously described.3 26
IMMUNOHISTOCHEMISTRY
Rat intestinal tissues obtained in the acute
phase of intestinal inflammation following
injection with either indomethacin (experi-
mental group) or buVer (control group) were
used. The B2 receptor in intestinal tissue was
detected using antipeptide antisera from rabbit
(a mixture of AS276 and AS283) to the rat B2
receptor (gift from Dr Werner Muller-Esterl,
Mainz, Germany) as a primary antibody,
produced and characterised as described
previously.27 The secondary antibody,
antirabbit-IgG-avidin-biotin complex, was
then added and was detected using an indirect
peroxidase technique (ABC Kit, Vector Labo-
ratories, Burlingame, California).
Rat intestinal tissue was embedded in paraf-
fin wax, cut into 5 µm thick sections, and
stained with haematoxylin and eosin for light
microscopy examination. The tissue sections
were then dewaxed, rehydrated in xylene and
alcohol, and washed in phosphate buVered
saline (PBS). The endogenous peroxidase was
blocked by incubation for 30 minutes in 0.3%
hydrogen peroxide in cold methanol. Then
sections were incubated with normal goat
serum for 30 minutes to reduce non-specific
binding. Sections were incubated with either
antipeptide antibodies to rat B2 receptor
(2.5–10 mg/ml), or normal rabbit IgG at the
same concentration as a control for one hour.
Antigen-antibody complexes were detected
with an antirabbit-IgG-biotinylated avidin-
horseradish peroxidase complex according to
the manufacturer’s instructions. Finally, the
sections were stained with 3,3'-
diaminobenzidine substrate and then counter-
stained with Mayer’s haematoxylin (Sigma).
STATISTICAL ANALYSIS
A group of female Lewis rats (n=10) that
received neither buVer nor indomethacin was
used to normalise the contact system data from
the control and indomethacin treated groups.
The unpaired two tailed Student’s t test28 was
Table 1 Intestinal inflammation in Lewis rats two and 14 days after subcutaneous injection with buVer or indomethacin
No of rats Gross gut score





inflammatory score IL-1â (pg/mg tissue)
Acute phase (2 days)
Indomethacin 13 4.1 (0.58)*** 14.3 (1.4)*** 26.4 (6)** 3.7 (0.3)*** 21.3 (5.0)**
Control 8 0 0 0 0.1 (0.03)† 5.3 (1.9)§
Chronic phase (14 days)
Indomethacin 8 10.3 (1.0)*** 7.0 (1.2)*** 36 (7.7)** 4.5 (0.7)*** 46.2 (11.4)
Control 7 0 0 0 0.2 (0.1)‡ 0.2 (0.03)‡
Results are expressed as mean (SEM).
**p<0.01, ***p<0.001.
†Performed on six indomethacin and four buVer treated rats; ‡performed on five indomethacin and four buVer treated rats; §performed on six indomethacin and seven
buVer treated rats.
Table 2 Body, liver and spleen weights and haematocrit in Lewis rats during the acute and chronic phases of
indomethacin induced inflammation




(mg/g body weight) Haematocrit (%)
Acute phase (2 days)
Indomethacin 13 172 (3.2)** 43.3 (1.4)** 3.2 (0.2)** 33 (1.6)***
Control 8 187 (3.2) 38.8 (0.5) 2.4 (0.1) 47 (0.9)
Chronic phase (14 days)
Indomethacin 8 155 (4)*** 59 (1.8)*** 8.0 (1.0)** 35 (2.8)***
Control 7 192 (3) 41 (0.5) 2.2 (0.1) 47 (1.5)
Results are expressed as mean (SEM).
**p<0.01, ***p<0.001.
368 Stadnicki, Sartor, Janardham, et al
used to evaluate diVerences between control
and treated groups; p values not greater than
0.05 were considered significant.
Results
INTESTINAL INFLAMMATION
Rats treated with two daily subcutaneous
injections of indomethacin developed acute
intestinal inflammation manifested grossly at
two days by thickening of the bowel wall and
mesentery, adhesions, and mesenteric haemor-
rhage. In addition, multiple small discrete
mucosal ulcers on the mesenteric side of the
small intestine were observed in the jejunum
and ileum. Ulcers were evident from the
serosed surface by focal thickening of the
mesentery. Superficial caecal ulceration was
present on the mucosal surface, but was not
visible externally and was not quantified in this
study. Mucosal blood was manifested by black
luminal contents in the mid and distal small
bowel, caecum, and colon; luminal contents
were strongly Haemoccult positive. Histologi-
cally, the ulcers showed necrosis of the entire
mucosa and severe serosal inflammation with
neutrophils and macrophages as the predomi-
nant infiltrating cells (fig 1A). At 14 days, rats
exhibited a more chronic inflammatory re-
sponse with dramatically thickened, adherent,
and hyperaemic mid small intestine (distal
jejunum to proximal ileum) with contraction
and thickening of the mesentery, and with
“creeping” mesenteric fat on the serosal
surface of the intestine (fig 2A). Deep, longitu-
dinal, or stellate mucosal ulcers were uniformly
present on the mesenteric border (fig 2B). No
intestinal bleeding or caecal ulcerations were
present. Histologically, ulcers and crypt ab-
scesses in the mucosa and transmural inflam-
mation with fibrosis, hyperplasia of smooth
muscle, and massive thickening of the submu-
cosa were present (fig 1B). The control rats
injected with buVer had no gross or histological
inflammatory changes and no ulcers.
Table 1 summarises the intestinal gross, his-
tological, and biochemical findings at days 2
and 14 following two daily subcutaneous injec-
tions of indomethacin or buVer. The mean
blinded gross gut score was most pronounced
in rats with chronic inflammation due to nota-
ble intestinal wall thickening and adhesions,
whereas the number of intestinal ulcers was
highest in rats during acute inflammation. The
percentage of surface area ulcerated was, how-
ever, larger at the chronic time point due to the
longitudinal nature of ulcers at 14 days. These
ulcers frequently extended for 5 cm (fig 1B).
The blinded histological inflammatory score
was notably increased over controls in both the
acute and chronic phases. Intestinal IL-1â
concentration, an index of macrophage activa-
tion, provided biochemical confirmation of the
gross and histological observations in both
phases of inflammation.
SYSTEMIC INFLAMMATION
Table 2 summarises the extraintestinal mani-
festations in rats treated with indomethacin
compared with controls. Two days after
indomethacin injection, rats had a significant
decrease in total body weight and significant
increases in absolute and normalised liver and
spleen weights. In addition, there was a statisti-
cally significant decrease in the haematocrit of
indomethacin injected rats, in part due to
intestinal bleeding. The chronic phase of
inflammation in indomethacin treated rats was
characterised by a significant decrease in total
body weight, a notable increase in spleen and
Figure 3 Functional assays of contact system proteins.
(A) Prekallikrein; (B) factor XI; (C) high molecular
weight kininogen. *p<0.05, **p<0.01, ***p<0.001. Solid
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liver weight, and a persistent anaemia when
compared with controls, despite the lack of
continued luminal blood loss.
BIOCHEMICAL ASSAYS OF CONTACT PROTEINS
The plasma protein concentration was found
to be moderately but significantly lower in rats
with acute inflammation than in control rats
(5.5 (0.3) versus 6.3 (0.1) g/dl, p<0.01). The
mean level of total protein in indomethacin
treated rats (5.5 (0.4) g/dl) during the chronic
phase was also lower compared with the
control group (6.2 (0.1) g/dl) but the difference
was not significant. Therefore, specific contact
protein values (µg/mg protein) were deter-
mined by dividing the prekallikrein, HK, or
factor XI concentrations by the total plasma
protein concentration. Rats injected with in-
domethacin exhibited a pronounced and sig-
nificant fall in PK functional levels at two days
and at 14 days compared with controls (fig
3A). Factor XI functional concentrations were
lower in experimental rats compared with con-
trols; however, the diVerence reached statistical
significance in the acute phase only (fig 3B).
The functional levels of HK were notably and
significantly decreased at two days and re-
mained significantly lower at 14 days in
indomethacin treated rats compared with
buVer treated rats (fig 3C).
To test further whether the kallikrein-kinin
system was activated in indomethacin treated
rats, representative plasma samples were evalu-
ated for the molecular weight distribution of
HK by western blotting. To define the changes
which might be expected, the contact system in
pooled normal Lewis rat plasma was activated
in vitro with kaolin and the pattern compared
with that in unactivated plasma. As seen in fig
4, an HK band (Mr = 120 kDa) is visualised in
lane 1 which represents normal pooled rat
plasma, which was not activated. In lane 2, the
band at 120 kDa is virtually absent, which
indicates HK cleavage. Although the protein
applied to the gel is identical, the control rat
plasma samples on lanes 3–5 have a higher
concentration of HK than plasma samples
from indomethacin treated chronically dis-
eased rats on lanes 6–8, suggesting cleavage of
HK in the latter group. The bands indicating
the HK cleavage product, heavy chain (HC-
HK) (Mr = 62 kDa) are visualised in plasma
activated in vitro (lane 2) and in rats with
inflammation (lanes 6–8), but not in control
plasma or in plasma of control rats (lanes 3–5).
A similar HK cleavage pattern was observed in
indomethacin treated rat plasma in the acute
phase of inflammation (not shown). Thus, this
assay indicates that in vivo cleavage of HK
occurs in rats with indomethacin induced
inflammation.
T KININOGEN LEVELS IN RAT PLASMA
T kininogen specific levels (as µg T kininogen
per mg total plasma protein) were significantly
increased in indomethacin treated rats com-
pared with controls rats at day 2 and remained
significantly higher than controls at day 14, as
shown in fig 5. Thus, T kininogen, a major
acute phase protein in the rat, is elevated in
both phases of inflammation.
IMMUNOHISTOCHEMICAL LOCALISATION OF B2
RECEPTORS IN RAT INTESTINE
The B2 receptor was visualised in normal as
well as in inflammatory rat intestine. Figures
6A–C illustrate the B2 receptor in normal
intestine. Some epithelial cells in the villi
display weak, focal immunoreactivities (fig
6A). At higher magnification (×400) of a villus,
focal staining is shown in cytoplasm of the epi-
thelial cells in the crypt (fig 6B). Immunostain-
ing is also present in the smooth muscle cells of
Figure 4 High molecular weight kininogen cleavage in Lewis rats treated with
indomethacin shown by western blotting using anti-high molecular weight kininogen
antibodies. Lane 1 shows pooled non-activated normal rat plasma (N), and lane 2 pooled
rat plasma following exposure to kaolin (K). Lanes 3–5 represent the plasma samples of
three control rats, while lanes 6–8 are plasma samples of rats 14 days after treatment with
indomethacin. The 120 kDa band represents HK and is visualised across lanes 1 and 3–8,
but is absent in lane 2. The broad band localised at about 68 kDa across all lanes indicates
cross reacting T kininogen (TK) and albumin. The band situated between albumin and the
43 kDa standard, visualised on lane 2 and lanes 6–8, but not on lane 1 and lanes 3–5,
represents the heavy chain of high molecular weight kininogen (HC-HK, 62 kDa). The
delicate band situated just above 32 kDa, standard across all lanes, represents a non-specific
reaction with alkaline phosphatase that hydrolyses the BCIP/NBT substrate used to develop
the colour.
Figure 5 Plasma T kininogen levels during acute phase
(two days) and chronic phase (14 days) of inflammation
after indomethacin injection (mean (SEM)). T kininogen
levels are expressed as µg/mg plasma protein. ***p<0.001.
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Figure 6 Immunolocalisation of the kinin B2 receptor in rat intestine on day 2. A–C: Rat normal control jejunum (buVer
treated). (A) Some focal staining positive for B2 receptor in the villi—V, occasionally in the muscularis mucosa below the
crypts—C, in the muscular layer—M, and in the serosa. Original magnification ×100. (B) Intestinal villi. Focal weak
immunostaining in the surface of occasional epithelial cells and in cytoplasm (arrow).Original magnification ×400. (C)
Some focal immunostaining, cluster of epithelial cells in crypts (large arrow), in the muscular layers (small solid arrows),
and in serosal surface (white arrows). Original magnification ×400.D–F: Rat inflamed intestine (day 2 after injection of
indomethacin). (D) Focal immunostaining in the villi—V, especially near the area of ulceration – U, in the internal and
external muscular layer—M, and in the serosa. Original magnification ×100. (E) Villus near area of ulceration showing
strong staining in the epithelial, probably absorptive cells (arrow).Original magnification ×400. (F) Prominent
immunostaining in the smooth muscle cells of the muscularis mucosa (solid arrows) and in the external muscular layer
(solid arrows). On the serosal surface, staining is also present (white arrows). Original magnification ×400.
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the muscular layer as well as on the serosal sur-
face (fig 6A,C). Note also weak nuclear
staining.
Figures 6D–F show specific staining of B2
receptors in inflamed rat intestine. Strong
immunostaining is present in some villi border-
ing areas of the ulceration (fig 6D). Higher
magnification of the villus (×400) shows strong
specific staining in the epithelial cells that show
histological features of absorptive cells (fig 6E).
Prominent immunostaining appears in the
smooth muscle cells of the muscularis mucosa
and in the internal and external layers of the
muscularis as well as on the serosal surface (fig
6D,F). The intestinal sections treated with
non-immune serum (rabbit IgG) instead of
anti-B2 receptor antibodies were always un-
stained (data not shown).
In general, more prominent immunostaining
in the epithelial cells of villi, smooth muscle
cells, and serosal surface was found in the sec-
tions of inflamed intestine compared with nor-
mal intestine.
Discussion
The indomethacin induced model of enteropa-
thy was described initially more than 25 years
ago.29 This agent, administered subcutaneously
or orally, has been found to produce small
intestinal and colonic ulcers in rodents in a
dose dependent fashion. Most early reports
evaluated only acute intestinal injury, because
investigators used doses greater than 10 mg/kg,
which were lethal, leading to intestinal perfora-
tion in two to four days.30 31 More recently, Sar-
tor et al16 modified this model using two suble-
thal daily doses of indomethacin (7.5 mg/kg) to
evaluate genetic susceptibility in inbred rats.16
This model induces acute intestinal injury
(peak two days), which evolves into chronic
intestinal inflammation lasting up to 11 weeks
in susceptible Lewis rats with associated
extraintestinal manifestations. To evaluate the
gross gut score, we used the same criteria as in
the PG-PS induced intestinal inflammatory
model. However, in contrast to intestinal
inflammation triggered by PG-PS, in which
mucosal ulceration was quite rare, the in-
domethacin model is characterised by large
numbers of ulcers in the mid small bowel.
Chronic inflammation displays gross and
histological features which in many aspects
mimic Crohn’s enteritis, such as bowel wall
thickening with linear ulcers, transmural in-
flammation with fibrosis, and “creeping fat” in
the mesentery. In addition, similar to Crohn’s
disease,32 indomethacin induced enterocolitis
is characterised by increased intestinal
permeability.33 34 Finally, this model exhibits a
genetic component: chronic inflammation de-
velops in genetically susceptible Lewis rats;
resistant Fisher rats display only mild, transient
injury16; and Sprague-Dawley rats develop
intermediate responses.34
The mechanisms of intestinal injury initiated
by indomethacin have not been entirely
defined. In the present study we measured
functional levels of the plasma contact proteins
to ascertain whether there was associated acti-
vation of the kallikrein-kinin system. The
decrease in plasma precursor proteins PK,
FXI, and HK indicates conversion of these
proteins to active enzymes (kallikrein and
factor XIa) and active cofactor (HKa). Activa-
tion of the contact system is even more striking
in the acute phase than in the acute PG-PS
induced model, as the decrease in PK and HK
is 50% and 35%, respectively, in rats treated
with indomethacin compared with controls, as
opposed to a 20% and 30% decrease in PK and
HK activities, respectively, in the acute phase of
PG-PS induced enterocolitis.3 The specific
plasma levels of each protein were calculated;
thus, the moderate decrease in total plasma
protein concentration in indomethacin treated
rats makes significant depletion of contact pro-
teins by intestinal leakage and/or decreased
liver synthesis much less likely. Furthermore,
increased plasma levels of the acute phase pro-
tein, T kininogen, confirms adequate hepatic
synthetic function in indomethacin treated
rats. In addition, our demonstration, for the
first time, of HK cleavage in diseased rats, but
not in control rats, strongly supports continued
activation of the contact system.
HK cleavage to HKa by plasma kallikrein
results in release of bradykinin, which directly
binds to and stimulates B2 receptors. The
present study visualises for the first time the B2
receptors in the intestine at the cellular level,
which provides a structural basis for the kinin
function. This finding agrees with the involve-
ment of bradykinin in acute inflammation. B2
receptors were shown in epithelial cells,
smooth muscle cells and, interestingly, also on
the serosal surface. Furthermore, more promi-
nent specific staining in inflamed tissue com-
pared with normal controls suggests that B2
receptor expression increases during inflam-
mation. In fact, recent in vivo data showed that
acute arthritis induced in rats by PG-PS is
mediated in part by bradykinin through the B2
receptor.35 The regulation of B2 receptor
expression during chronic inflammation will
require future study using quantitative meth-
ods. B2 receptors are not apparently up
regulated during chronic inflammation, during
which B1 receptors play a major role.10 There-
fore, we did not study the constitutively
expressed B2 receptors at 14 days. Unfortu-
nately, antibodies against the inducible B1
receptor in rats are still not available. Bradyki-
nin itself cannot be measured accurately
because of its short (less than 30 seconds) half-
life in vivo and the diYculty in preventing in
vitro release during blood collection.
The contact activation in this model may
reflect the pathophysiological response to
intestinal tissue injury. The possible mecha-
nisms are not clear, as potential factors such as
endothelial perturbation, leucocyte stimula-
tion, or the presence of bacterial proteases in
the circulation have not been completely
defined in indomethacin initiated intestinal
inflammation. However, in the present study
we show the impressive increase in plasma T
kininogen levels in indomethacin treated rats,
which reflects an acute phase reaction.36 The
synthesis of acute phase proteins in the liver is
known to be triggered by interleukin 6. As
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interleukin 6 expression requires interleukin 1
(IL-1), a key proinflammatory cytokine, this
acute phase response in indomethacin treated
rats suggests the stimulation of monocytes
and/or endothelial cells, which leads to IL-1
release. Our results document significant in-
creases in intestinal IL-1â in acute and chronic
phases of inflammation. A pathogenic role of
IL-1 is further suggested by the preliminary
results of Sartor et al,37 who reported that
recombinant IL-1 receptor antagonist dimin-
ished acute and chronic inflammation induced
by indomethacin in Lewis rats. Furthermore,
IL-6 is known to mediate anaemia in chronic
diseases,38 which may explain the sustained fall
in haematocrit in the chronic phase of our
model despite the lack of mucosal blood loss.
Anaemia in the acute phase is probably caused
in part by moderate intestinal bleeding, which
is observed more frequently in the mid small
intestine than in the stomach in this model.
Several factors have been postulated to initi-
ate and perpetuate an increase in intestinal
permeability and ulcerations, the most charac-
teristic morphological changes in indometh-
acin initiated experimental enteropathy.32 Most
attention has been paid to alterations of arachi-
donic acid metabolism. In human and experi-
mental IBD, thromboxanes and leukotrienes
are proinflammatory, whereas prostaglandins
are protective.2 Previous studies39 40 indicated
that inhibition of prostaglandins can lead to
epithelial damage in the gastrointestinal tract.
However, other metabolic pathways of arachi-
donic acid are also important because in-
domethacin induced intestinal lesions were
prevented or treated by thromboxane syn-
thetase inhibitors34 as well as inhibitors of
5-lipooxygenase.41 The lipooxygenase pathway
product, leukotriene B4, is thought to be
derived predominantly from neutrophils in the
intestine.
Neutrophil accumulation, reflected by histo-
logical score and increased myeloperoxidase
(MPO) concentration, is evident in enterocoli-
tis induced by indomethacin.16 34 Neutrophilic
infiltration was a prominent feature of both
acute and chronic phases of indomethacin
induced small intestinal injury in Lewis rats. In
this model there is a six- to eightfold increase in
leucocyte endothelial cell adherence and
emigration.42 Neutrophil induced tissue injury
is thought to be predominantly mediated by
extracellular secretion of lysosomal enzymes
and superoxide.43 As kallikrein is a known che-
moattractant for neutrophils and stimulates
elastase release,7 8 activation of the kallikrein-
kinin system may be one of the stimuli of neu-
trophil related injury. In our PG-PS induced
enterocolitis model, we showed that a specific
kallikrein inhibitor decreased intestinal MPO
activity,5 which strongly indicates a pathogenic
relation between kallikrein-kinin activation and
intestinal neutrophil recruitment.
The current experimental model is in many
aspects diVerent from PG-PS induced entero-
colitis, including the fact that the triggering
agent is not an exogenous bacterial polymer.
However, previous investigations have shown
that resident luminal bacteria strongly contrib-
ute to the inflammatory response in rats treated
by indomethacin. Small intestinal inflamma-
tion induced by indomethacin has been shown
to be inhibited or treated by broad spectrum
antibiotics,30 34 whereas acute arthritis is at-
tenuated and chronic inflammation does not
occur in germ free (sterile) Lewis rats.44 The
results of Yamada and coworkers34 indicated
that the chronic phase, but not the acute phase
of indomethacin induced enterocolitis, is at-
tenuated by metronidazole, and hence may be
mediated by luminal anaerobic bacteria. Fur-
thermore, these authors showed enhanced
translocation of intestinal bacteria to me-
senteric lymph nodes after indomethacin
exposure. However, in the current model, in
which acute inflammation evolves into chronic
mid small bowel ulceration, we show activation
of the kallikrein-kinin system in both acute and
chronic phases. It is possible that ubiquitous
intestinal bacterial constituents, as well as
exogenous bacterial products such as PG-PS
and LPS, are responsible for activation of the
contact system, in keeping with observations in
experimental and clinical septic shock.13–15
The biochemical andmorphological changes
observed in our experimental animal model
may have relevance to human enteropathies,
especially IBD. Chronic administration of cer-
tain non-steroidal anti-inflammatory drugs
(NSAIDs) such as indomethacin to humans
increased small intestinal permeability,45 which
has long been recognised as an early pathologi-
cal change in Crohn’s disease.1 33 Furthermore,
Bjarnason and coworkers46 have shown that
NSAIDs cause small intestinal inflammation,
in some cases with strictures, in two thirds of
patients during long term treatment. These
drugs also emerged as an important factor in
the relapse of patients with ulcerative colitis.47
Recently, we have shown that activation of the
kallikrein-kinin system occurs in patients with
active ulcerative colitis,48 and that acute5 and
chronic12 PG-PS induced enterocolitis in the
rat is inhibited by a specific kallikrein inhibitor.
Whether kallikrein-kinin system activation par-
ticipates in human enteropathy caused or
aggravated by indomethacin remains to be
investigated. Taken together, these results show
that kallikrein-kinin system activation occurs in
experimental and human intestinal inflamma-
tion of diverse aetiologies, suggesting that the
contact system is an important mediator of
enterocolitis and could provide a target for
therapeutic intervention.
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